Preclinical characterization of WAY-211612: A dual 5-HT uptake inhibitor and 5-HT 1A receptor antagonist and potential novel antidepressant

British Journal of Pharmacology

Volumn 157, Issue 2, 2009, Pages 307-319

  Beyer, C E ^a   Lin, Q ^a   Platt, B ^a   Malberg, J ^a   Hornby, G ^a   Sullivan, K M ^a   Smith, D L ^a   Lock, T ^a   Mitchell, P J ^b   Hatzenbuhler, N T ^a   Evrard, D A ^a   Harrison, B L ^a   Magolda, R ^a   Pangalos, M N ^a   Schechter, L E ^a   Rosenzweig Lipson, S ^a   Andree, T H ^a  

^a PFIZER INC   (United States)

^b University of Bath   (United Kingdom)

Author keywords

Antidepressant; Depression; Fluoxetine; Rodent; Serotonin; microdialysis

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; WAY 211612; CYCLIC AMP; SEROTONIN 1A RECEPTOR; SEROTONIN ANTAGONIST;

AGGRESSION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HIPPOCAMPUS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; DRUG ANTAGONISM; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MICRODIALYSIS; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLIC AMP; MALE; MICE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 68549135115     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00146.x     Document Type: Article

References (55)

1. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F (2005). Strategies for producing faster acting antidepressants. Drug Discovery Today 10: 578-585. (Pubitemid 40552825)
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition (2008 revision). Br f Pharmacol 153 (Suppl. 2): S1-S209.
3. Arborelius L, Wallsten C, Ahlenius S, Svensson TH (1999). The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. Eur J Pharmacol 382: 133-138. (Pubitemid 29488746)
4. Artigas F, Perez V, Alvarez E (1994). Pindolol induces a rapid Improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51: 248-251. (Pubitemid 24081512)
5. Artigas F, Romero L, de Montigny C, Blier P (1996). Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19: 378-383. (Pubitemid 26270513)
6. Artigas F, Adell A, Celada P (2006). Pindolol augmentation of antidepressant response. Curr Drug Targets 7: 139-147.
7. Ballesteros J, Callado LF (2004). Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affective Disorders 79: 137-147. (Pubitemid 38340537)
8. Berman RM, Darnell AM, Miller HL, Anand A, Charney DS (1997). Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154: 37-43. (Pubitemid 27020190)
9. Beyer CE, Cremers TIFH (2008). Do selective serotonin reuptake inhibitors acutely increase frontal cortex levels of serotonin? Eur J Pharmacol 580: 350-354.
10. Beyer CE, Boikess S, Luo B, Dawson LA (2002). Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharm 16: 297-304. (Pubitemid 35470573)
11. Blier P, Bergeron R (1995). Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15: 217-222.
12. Blier P, Bergeron R (1998). The use of pindolol to potentiate antidepressant medication. J Clin Psychiatry 59 (Suppl. 5): 16-23; discussion 24-25. (Pubitemid 28249103)
13. Blier P, de Montigny C (1994). Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15: 220-226. (Pubitemid 24210726)
14. Chaput Y, de Montigny C, Blier P (1986). Effects of a selective 5-HT reuptake blocker, Citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 333: 342-348. (Pubitemid 16023193)
15. 3H] 5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 32: 737-743.
16. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
17. Cryan JF, Redmond AM, Kelly JP, Leonard BE (1997). The effects of the 5 HT1A agonist flesinoxan, In three paradigms for assessing antidepressantpotential in the rat. Eur Neuropsychopharmacol 7: 109-114.
18. Dawson LA, Nguyen HQ (1998). Effects of the 5-HT1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur J Pharmacol 345: 41-46.
19. Done C, Sharp T (1994). Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 33: 411-421. (Pubitemid 124015963)
20. Duxon MS, Starr KR, Upton N (2000). Latency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(IA) receptor antagonist WAY100635. Br J Pharmacol 130: 1713-1719.
21. Evrard DA, Zhou P, Yi SY, Zhou D, Smith DL, Sullivan KM et al (2005). Studies towards the next generation of antidepressants. Part 4: derivatives of 4-(5-fluoro-1H-indol-3-yl)cyclohexylamine with affinity for the serotonin transporter and the 5-HT1A receptor. Bioorg Med Chem Lett 15: 911-914. (Pubitemid 40458622)
22. Gartside SE, Umbers V, Hajos M, Sharp T (1995). Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol 115: 1064-1070.
23. Gartside SE, Clifford EM, Cowen PJ, Sharp T (1999). Effects of (-)tertatolol, (-)-penbutolol and (±)-pindolol in combination with paroxetine on presynaptic 5-HT function: an in vivo microdialysis and electrophysiological study. Br J Pharmacol 127: 145-152.
24. Gobert A, Rivet J, Audinot V, Newman-Tancredi A, Cistarelli L, Millan M (1998). Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freelymoving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84: 413429. (Pubitemid 28122907)
25. Golden RN (2004). Making advances where it matters: improving outcomes in mood and anxiety disorders. CNS Spectr 9 (6 Suppl. 4): 14-22.
26. Hascoet M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000). Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65: 339-344. (Pubitemid 30100282)
27. Hatzenbuhler NTE, Harrison DA, Huryn BL, Inghrim D, Kraml J, Mattes C et al. (2006). Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity. J Med Chem 49: 4785-4789.
28. Hervas I, Vilaro MT, Romero L, Scorza MC, Mengod G, Artigas F (2001). Desensitization of 5-HT1A autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY100635. Neuropsychopharmacology 24: 11-20.
29. Hjorth S, Westlin D, Bengtsson HJ (1997). WAY-100635-induced augmentation of the 5-HT elevating action of Citalopram - relative importance of the dose of the 5-HT1A (auto)receptor blocker vs. that of the 5-HT reuptake inhibitor. Neuropharmacology 36: 461465. (Pubitemid 27272091)
30. Hogg S, Dalvi A (2004). Acceleration of onset of action in scheduleinduced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists. Pharmacol Biochem Behav 77: 69-75. (Pubitemid 38076982)
31. Hughes ZA, Sharp T (1998). Evidence that pindolol lacks the ability to enhance the effect of SSRIs on presynaptic 5-HT function. Br J Pharmacol 125: 6P.
32. Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ et al. (2005). Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. Eur J Pharmacol 510: 49-57. (Pubitemid 40312389)
33. Invernizzi R, Belli S, Samanin R (1992). Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584: 322-324.
34. Invernizzi R, Bramante M, Samanin R (1996). Role of 5-HT1A receptors in the effectsof acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav 54: 143147. (Pubitemid 26146667)
35. Kreiss DS, Lucki I (1995). Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274: 866-876.
36. Lazareno S, Birdsall NJ (1993). Pharmacological characterization of acetylcholilne-stimulated [35S]-GTP gamma S binding mediated by human muscarinic ml-m4 receptors: antagonist studies. Br J Pharmacol 109: 1120-1127. (Pubitemid 23216781)
37. Malberg JE, Piatt B, Rizzo SJ, Ring RH, Lucki I, Schechter LE et al. (2007). Increasing the levels of insulin-like growth factor-i by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 32: 23602368. (Pubitemid 47587671)
38. Mewshaw RE, Zhou D, Zhou P, Shi X, Hornby G, Spangler T et al. (2004). Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N- aryloxyethylindolylalkylamines. J Med Chem 47: 3823-3842. (Pubitemid 38900348)
39. Millan MJ (2006). Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pliarmacol Ther 110: 135-370.
40. Mitchell PJ (2005). Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526: 147-162.
41. Mitchell PJ, Redfern PH (1997). Potentiation of the time-dependent, antidepressant-induced changes in the agonistic behaviour of resident rats by the 5-HT1A receptor antagonist, WAY-100635. Behav Pharmacol 8: 585-606.
42. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
43. Pranzatelli MR (1990). Evidence for the involvement of 5-HT2 and 5-HT1C receptors in the behavioural effects of the 5-HT agonist l-(2,5-dimethoxy-4- iodophenyl)-2-aminopropane (DOI). Neurosci Lett 115: 74-80.
44. Ramamoorthy JD, Ramamoorthy S, Papapetropoulos A, Catravas JD, Leibach FH, Ganapathy V (1995). Cyclic AMP-independent upregulation of the human serotonin transporter by staurosporine in choriocarcinoma cells. J Biol Chem 270: 17189-17195.
45. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B et al. (2006). Anxiolytic-like activity of oxytocin in male mice: behavioural and autonomic evidence, therapeutic implications. Psychopharmacology (Berl) 185: 218-225. (Pubitemid 43363618)
46. Rocco VP, Spinazze PG, Kohn TJ, Honigschmidt NA, Nelson DL, Bradley Wainscott D et al. (2004). Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 4. Bioorg Med Chem Lett 14: 2653-2656. (Pubitemid 38515721)
47. Romero L, Artigas F (1997). Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem 68: 2593-2603. (Pubitemid 27218184)
48. Schechter LE, Ring RH, Beyer CE, Hughes ZA, Khawaja X, Malberg JE et al. (2005). Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2: 590-611.
49. Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995). DOI-induced Head-Twitches in the rat are mediated by 5-HT2A receptors: modulation by novel 5-HT2A/C receptor antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273: 101112.
50. Sharp T, Umbers V, Gartside SE (1997). Effect of a selective 5-HT reuptake inhibitor in combination with 5-TH1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol 121: 941-946. (Pubitemid 27277788)
51. 2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behaviour in rats. Psychopharmacology 150: 422-429.
52. Watson JM, Dawson LA (2007). Characterization of the potent 5-HT(lA/B) receptor antagonist and serotonin reuptake inhibitor SB-649915: preclinical evidence for hastened onset of antidepressant/anxiolytic efficacy. CNS Drug Rev 13: 206-223.
53. Wesolowska A, Paluchowska MH, Golembiowska K, ChojnackaWojcik E (2003). Pharmacological characterization of MP349, a novel 5-HT1A-receptor antagonist with anxiolytic-like activity, in mice and rats. J Pharm Pharmacol 55: 533-543. (Pubitemid 36591906)
54. Woods A, Smith C, Szewczak M, Dunn RW, Comfeldt M, Corbett R (1993). Selective serotonin re-uptake inhibitors decrease scheduleinduced polydipsia in rats: a potential model for obsessive compulsive disorder. Psychopharmacology 112: 195-198. (Pubitemid 23278278)
55. Yoshino T, Nisijima K, Katoh S, Yui K, Nakamura M (2002). Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochem Int 40: 355-360. (Pubitemid 34131610)